Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd completed the acquisition of 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng.
August 09, 2022
Share
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) agreed to acquire 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng for approximately CNY 140 million on July 20, 2022. Ningxia Delixin Medicine Co., Ltd generated the Total Assets of CNY 166.235 million and Net Assets of CNY 31.2436 million for June 2022. Transaction is approved by Board of directors of Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd.
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) completed the acquisition of 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng on August 10, 2022.
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is a China-based company mainly engaged in the distribution and retail business of drugs, biological products, medical devices and other products. The Company is also engaged in reproductive hospital business. The pharmaceutical distribution business includes pure sales mode and allocation mode, mainly engaged in anti-tumor drugs, immunomodulatory drugs, cardiovascular and cerebrovascular drugs, respiratory drugs, antiviral drugs and other new and special drugs. The pharmaceutical retail business is mainly engaged in professional pharmacies, focusing on the sales of prescription drugs, mainly including Special Service pharmacy business and direct to patient (DTP) pharmacy business. The reproductive hospital business is mainly engaged in the diagnosis and treatment of gynecological and urological diseases.
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd completed the acquisition of 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng.